Literature DB >> 3874022

Interleukin-1 production by mononuclear cells from patients with scleroderma.

C I Sandborg, M A Berman, B S Andrews, G J Friou.   

Abstract

Interleukin-1 (IL-1) production by peripheral blood mononuclear cells (PBMC) from patients with scleroderma and healthy controls was studied. Supernatants from unstimulated PBMC cultures from 10 of 13 patients with progressive systemic sclerosis (PSS) had significantly less IL-1 activity as measured by thymocyte proliferation than controls. IL-1 activity per monocyte/macrophage in both patients and controls was 10 times greater when PBMC were cultured at 10(5) cells/ml compared to 10(6) cells/ml. Five-fold dilution of supernatants from PBMC cultured at 10(6) cells/ml revealed more IL-1 activity than undiluted supernatant and addition of indomethacin increased IL-1 activity primarily of the undiluted supernatant. The results show that IL-1 activity from crude PBMC supernatants from PSS patients is low and may be regulated by non-dialysable inhibitors produced by PBMC and/or cell interactions.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3874022      PMCID: PMC1577042     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  25 in total

1.  Lymphocyte-activating factor. I. Generation and physicochemical characterization.

Authors:  J S Economou; H S Shin
Journal:  J Immunol       Date:  1978-10       Impact factor: 5.422

2.  Ability of dialysates containing transfer factor to induce lymphocyte activating factor by human mononuclear cells.

Authors:  A Togawa; J J Oppenheim; C H Kirkpatrick
Journal:  Cell Immunol       Date:  1979-06       Impact factor: 4.868

3.  Cytochemical identification of monocytes and granulocytes.

Authors:  L T Yam; C Y Li; W H Crosby
Journal:  Am J Clin Pathol       Date:  1971-03       Impact factor: 2.493

4.  T cell growth factor: parameters of production and a quantitative microassay for activity.

Authors:  S Gillis; M M Ferm; W Ou; K A Smith
Journal:  J Immunol       Date:  1978-06       Impact factor: 5.422

5.  Endogenous pyrogens made by rabbit peritoneal exudate cells are identical with lymphocyte-activating factors made by rabbit alveolar macrophages.

Authors:  P A Murphy; P L Simon; W F Willoughby
Journal:  J Immunol       Date:  1980-05       Impact factor: 5.422

6.  Components of mycobacteria and muramyl dipeptide with adjuvant activity induce lymphocyte activating factor.

Authors:  J J Oppenheim; A Togawa; L Chedid; S Mizel
Journal:  Cell Immunol       Date:  1980-03-01       Impact factor: 4.868

7.  Phorbol myristic acetate stimulates LAF production by the macrophage cell line, P388D.

Authors:  S B Mizel; D L Rosenstreich; J J Oppenheim
Journal:  Cell Immunol       Date:  1978-09-15       Impact factor: 4.868

8.  Glioblastoma cells release interleukin 1 and factors inhibiting interleukin 2-mediated effects.

Authors:  A Fontana; H Hengartner; N de Tribolet; E Weber
Journal:  J Immunol       Date:  1984-04       Impact factor: 5.422

9.  Mononuclear cell modulation of connective tissue function: suppression of fibroblast growth by stimulation of endogenous prostaglandin production.

Authors:  J H Korn; P V Halushka; E C LeRoy
Journal:  J Clin Invest       Date:  1980-02       Impact factor: 14.808

10.  Production of lymphocyte-activating factor (Interleukin 1) by macrophages activated with colony-stimulating factors.

Authors:  R N Moore; J J Oppenheim; J J Farrar; C S Carter; A Waheed; R K Shadduck
Journal:  J Immunol       Date:  1980-09       Impact factor: 5.422

View more
  8 in total

1.  In vivo levels and in vitro production of interferon-gamma in fibrosing interstitial lung diseases.

Authors:  C Prior; P L Haslam
Journal:  Clin Exp Immunol       Date:  1992-05       Impact factor: 4.330

2.  The effects of selected drugs, including chlorpromazine and non-steroidal anti-inflammatory agents, on polyclonal IgG synthesis and interleukin 1 production by human peripheral blood mononuclear cells in vitro.

Authors:  F Martinez; J W Coleman
Journal:  Clin Exp Immunol       Date:  1989-05       Impact factor: 4.330

3.  Mechanism of a lymphocyte abnormality associated with HLA-B8/DR3: role of interleukin-1.

Authors:  S Hashimoto; J P Michalski; M A Berman; C McCombs
Journal:  Clin Exp Immunol       Date:  1990-02       Impact factor: 4.330

4.  Association of interleukin 1 family with systemic sclerosis.

Authors:  Li Zhang; Jun-Wei Yan; Yu-Jie Wang; Ya-Nan Wan; Bing-Xiang Wang; Jin-Hui Tao; Bing Chen; Bao-Zhu Li; Guo-Jun Yang; Jing Wang
Journal:  Inflammation       Date:  2014-08       Impact factor: 4.092

5.  Defective production of leucocytic endogenous mediator (interleukin 1) by peripheral blood leucocytes of patients with systemic sclerosis, systemic lupus erythematosus, rheumatoid arthritis and mixed connective tissue disease.

Authors:  J T Whicher; A M Gilbert; C Westacott; C Hutton; P A Dieppe
Journal:  Clin Exp Immunol       Date:  1986-07       Impact factor: 4.330

6.  Multiple clinical and biological autoimmune manifestations in 50 workers after occupational exposure to silica.

Authors:  J Sanchez-Roman; I Wichmann; J Salaberri; J M Varela; A Nuñez-Roldan
Journal:  Ann Rheum Dis       Date:  1993-07       Impact factor: 19.103

7.  Increased production of an interleukin 1 (IL-1) inhibitor with fibroblast stimulating activity by mononuclear cells from patients with scleroderma.

Authors:  C I Sandborg; M A Berman; B S Andrews; G R Mirick; G J Friou
Journal:  Clin Exp Immunol       Date:  1986-11       Impact factor: 4.330

8.  Studies of an interleukin 1 inhibitor: characterization and clinical significance.

Authors:  M A Berman; C I Sandborg; B S Calabia; B S Andrews; G J Friou
Journal:  Clin Exp Immunol       Date:  1986-04       Impact factor: 4.330

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.